This event is not part of ACC.22 and is not sponsored or endorsed by the American College of Cardiology. This event does not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.
Friday, April 1, 2022
6:00PM – 6:30PM Local Time: Registration & Dinner
6:30PM – 7:30PM Local Time: Symposium
Marriott Marquis Washington DC
Liberty Salon L
901 Massachusetts Ave NW
Washington, DC 20001
PROGRAM FEATURES
- Interactive, case-based learning environment
- Downloadable Whiteboard Animations
- Make your own complimentary poster for your officeboard animations
FACULTY
George Bakris, MD, FASH, FASN, FAHA
Professor of Medicine
Director, American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL
Robert Toto, MD
Medical Director of the Multi-Specialty Clinic at UT Southwestern Medical Center
Associate Dean of Clinical and Translational Research in the Graduate School of Biomedical Sciences Director of the Center for Translational Medicine
UT Southwestern Multispecialty Clinic
Dallas, TX
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Review the mechanistic features of novel mineralocorticoid receptor antagonists and differentiate these therapies from earlier mineralocorticoid receptor antagonists
- Evaluate CKD risk in patients with T2D and clinical data with novel mineralocorticoid receptor antagonists to manage the risk of renal deterioration
- Summarize strategies for the management of hyperkalemia in patients receiving mineralocorticoid receptor antagonists
TARGET AUDIENCE
This activity is designed to meet the educational needs of cardiologists and other healthcare practitioners to ensure recognition of CKD risk in patients with T2D and novel strategies for modifying cardiovascular and renal risk in patients with T2D.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For questions, please contact Med Learning Group at [email protected]
Contact this provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at [email protected]
